Anaplastic large cell lymphoma Hodgkin's-like: A randomized trial of ABVD versus MACOP-B with and without radiation therapy

Pier Luigi Zinzani, Maurizio Martelli, Massimo Magagnoli, Alfonso Zaccaria, Fioravante Ronconi, Maria Cantonetti, Monica Bocchia, Roberto Marra, Marco Gobbi, Brunangelo Falini, Filippo Gherlinzoni, Luciano Moretti, Amalia De Renzo, Patrizio Mazza, Enzo Pavone, Elena Sabattini, Angela Amendola, Maurizio Bendandi, Stefano A. Pileri, Franco MandelliSante Tura

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

During the last few years, morphological, immunohistochemical, and genetic findings have placed anaplastic large cell lymphoma (ALCL) as a distinct clinicopathologic entity, and several reports have focused on the existence of different subtypes of the tumor. Particular attention has been paid to the ALCL-Hodgkin's-like (HL) subtype, which seems to be on the border between Hodgkin's disease (HD) and high-grade non-Hodgkin's lymphoma (HG- NHL). From September 1994 to July 1997, during the course of an Italian multicentric trial, 40 ALCL-HLs were randomized to receive as front-line chemotherapy MACOP-B (methotrexate with leucovorin, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin - a third- generation HG-NHL regimen) or ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine - a scheme specific for HD). All patients with bulky disease in the mediastinum at diagnosis underwent local radiotherapy after the chemotherapeutic program. Complete response (CR) was achieved in 17 of the 19 (90%) patients who were treated with MACOP-B, and in 19 of the 21 (91%) patients who were administered ABVD. The probability of relapse-free survival, projected at 32 months, was 94% for the MACOP-B subset and 91% for the ABVD subset. The majority of patients with mediastinal bulky disease obtained CR (evaluated with 67Ga single photon emission computed tomography [SPECT]) after their radiotherapy. The present study suggests that ALCL-HL, in line with its borderline status, responds in an equivalent way to third- generation chemotherapy for HG-NHL and to conventional HD treatment in terms of both CR and relapse-free survival rates. However, as to the latter, a longer follow-up period may be needed before stating the absolute equivalence of the two regimens used.

Original languageEnglish
Pages (from-to)790-794
Number of pages5
JournalBlood
Volume92
Issue number3
Publication statusPublished - Aug 1 1998

Fingerprint

Anaplastic Large-Cell Lymphoma
Radiotherapy
Hodgkin Disease
Chemotherapy
Bleomycin
Non-Hodgkin's Lymphoma
Doxorubicin
Mediastinal Diseases
Single photon emission computed tomography
Recurrence
Drug Therapy
Dacarbazine
Leucovorin
Vinblastine
Mediastinum
Vincristine
Prednisone
Single-Photon Emission-Computed Tomography
Methotrexate
Cyclophosphamide

ASJC Scopus subject areas

  • Hematology

Cite this

Zinzani, P. L., Martelli, M., Magagnoli, M., Zaccaria, A., Ronconi, F., Cantonetti, M., ... Tura, S. (1998). Anaplastic large cell lymphoma Hodgkin's-like: A randomized trial of ABVD versus MACOP-B with and without radiation therapy. Blood, 92(3), 790-794.

Anaplastic large cell lymphoma Hodgkin's-like : A randomized trial of ABVD versus MACOP-B with and without radiation therapy. / Zinzani, Pier Luigi; Martelli, Maurizio; Magagnoli, Massimo; Zaccaria, Alfonso; Ronconi, Fioravante; Cantonetti, Maria; Bocchia, Monica; Marra, Roberto; Gobbi, Marco; Falini, Brunangelo; Gherlinzoni, Filippo; Moretti, Luciano; De Renzo, Amalia; Mazza, Patrizio; Pavone, Enzo; Sabattini, Elena; Amendola, Angela; Bendandi, Maurizio; Pileri, Stefano A.; Mandelli, Franco; Tura, Sante.

In: Blood, Vol. 92, No. 3, 01.08.1998, p. 790-794.

Research output: Contribution to journalArticle

Zinzani, PL, Martelli, M, Magagnoli, M, Zaccaria, A, Ronconi, F, Cantonetti, M, Bocchia, M, Marra, R, Gobbi, M, Falini, B, Gherlinzoni, F, Moretti, L, De Renzo, A, Mazza, P, Pavone, E, Sabattini, E, Amendola, A, Bendandi, M, Pileri, SA, Mandelli, F & Tura, S 1998, 'Anaplastic large cell lymphoma Hodgkin's-like: A randomized trial of ABVD versus MACOP-B with and without radiation therapy', Blood, vol. 92, no. 3, pp. 790-794.
Zinzani PL, Martelli M, Magagnoli M, Zaccaria A, Ronconi F, Cantonetti M et al. Anaplastic large cell lymphoma Hodgkin's-like: A randomized trial of ABVD versus MACOP-B with and without radiation therapy. Blood. 1998 Aug 1;92(3):790-794.
Zinzani, Pier Luigi ; Martelli, Maurizio ; Magagnoli, Massimo ; Zaccaria, Alfonso ; Ronconi, Fioravante ; Cantonetti, Maria ; Bocchia, Monica ; Marra, Roberto ; Gobbi, Marco ; Falini, Brunangelo ; Gherlinzoni, Filippo ; Moretti, Luciano ; De Renzo, Amalia ; Mazza, Patrizio ; Pavone, Enzo ; Sabattini, Elena ; Amendola, Angela ; Bendandi, Maurizio ; Pileri, Stefano A. ; Mandelli, Franco ; Tura, Sante. / Anaplastic large cell lymphoma Hodgkin's-like : A randomized trial of ABVD versus MACOP-B with and without radiation therapy. In: Blood. 1998 ; Vol. 92, No. 3. pp. 790-794.
@article{baae9e11844d4e1f84d772f17f383fb4,
title = "Anaplastic large cell lymphoma Hodgkin's-like: A randomized trial of ABVD versus MACOP-B with and without radiation therapy",
abstract = "During the last few years, morphological, immunohistochemical, and genetic findings have placed anaplastic large cell lymphoma (ALCL) as a distinct clinicopathologic entity, and several reports have focused on the existence of different subtypes of the tumor. Particular attention has been paid to the ALCL-Hodgkin's-like (HL) subtype, which seems to be on the border between Hodgkin's disease (HD) and high-grade non-Hodgkin's lymphoma (HG- NHL). From September 1994 to July 1997, during the course of an Italian multicentric trial, 40 ALCL-HLs were randomized to receive as front-line chemotherapy MACOP-B (methotrexate with leucovorin, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin - a third- generation HG-NHL regimen) or ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine - a scheme specific for HD). All patients with bulky disease in the mediastinum at diagnosis underwent local radiotherapy after the chemotherapeutic program. Complete response (CR) was achieved in 17 of the 19 (90{\%}) patients who were treated with MACOP-B, and in 19 of the 21 (91{\%}) patients who were administered ABVD. The probability of relapse-free survival, projected at 32 months, was 94{\%} for the MACOP-B subset and 91{\%} for the ABVD subset. The majority of patients with mediastinal bulky disease obtained CR (evaluated with 67Ga single photon emission computed tomography [SPECT]) after their radiotherapy. The present study suggests that ALCL-HL, in line with its borderline status, responds in an equivalent way to third- generation chemotherapy for HG-NHL and to conventional HD treatment in terms of both CR and relapse-free survival rates. However, as to the latter, a longer follow-up period may be needed before stating the absolute equivalence of the two regimens used.",
author = "Zinzani, {Pier Luigi} and Maurizio Martelli and Massimo Magagnoli and Alfonso Zaccaria and Fioravante Ronconi and Maria Cantonetti and Monica Bocchia and Roberto Marra and Marco Gobbi and Brunangelo Falini and Filippo Gherlinzoni and Luciano Moretti and {De Renzo}, Amalia and Patrizio Mazza and Enzo Pavone and Elena Sabattini and Angela Amendola and Maurizio Bendandi and Pileri, {Stefano A.} and Franco Mandelli and Sante Tura",
year = "1998",
month = "8",
day = "1",
language = "English",
volume = "92",
pages = "790--794",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "3",

}

TY - JOUR

T1 - Anaplastic large cell lymphoma Hodgkin's-like

T2 - A randomized trial of ABVD versus MACOP-B with and without radiation therapy

AU - Zinzani, Pier Luigi

AU - Martelli, Maurizio

AU - Magagnoli, Massimo

AU - Zaccaria, Alfonso

AU - Ronconi, Fioravante

AU - Cantonetti, Maria

AU - Bocchia, Monica

AU - Marra, Roberto

AU - Gobbi, Marco

AU - Falini, Brunangelo

AU - Gherlinzoni, Filippo

AU - Moretti, Luciano

AU - De Renzo, Amalia

AU - Mazza, Patrizio

AU - Pavone, Enzo

AU - Sabattini, Elena

AU - Amendola, Angela

AU - Bendandi, Maurizio

AU - Pileri, Stefano A.

AU - Mandelli, Franco

AU - Tura, Sante

PY - 1998/8/1

Y1 - 1998/8/1

N2 - During the last few years, morphological, immunohistochemical, and genetic findings have placed anaplastic large cell lymphoma (ALCL) as a distinct clinicopathologic entity, and several reports have focused on the existence of different subtypes of the tumor. Particular attention has been paid to the ALCL-Hodgkin's-like (HL) subtype, which seems to be on the border between Hodgkin's disease (HD) and high-grade non-Hodgkin's lymphoma (HG- NHL). From September 1994 to July 1997, during the course of an Italian multicentric trial, 40 ALCL-HLs were randomized to receive as front-line chemotherapy MACOP-B (methotrexate with leucovorin, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin - a third- generation HG-NHL regimen) or ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine - a scheme specific for HD). All patients with bulky disease in the mediastinum at diagnosis underwent local radiotherapy after the chemotherapeutic program. Complete response (CR) was achieved in 17 of the 19 (90%) patients who were treated with MACOP-B, and in 19 of the 21 (91%) patients who were administered ABVD. The probability of relapse-free survival, projected at 32 months, was 94% for the MACOP-B subset and 91% for the ABVD subset. The majority of patients with mediastinal bulky disease obtained CR (evaluated with 67Ga single photon emission computed tomography [SPECT]) after their radiotherapy. The present study suggests that ALCL-HL, in line with its borderline status, responds in an equivalent way to third- generation chemotherapy for HG-NHL and to conventional HD treatment in terms of both CR and relapse-free survival rates. However, as to the latter, a longer follow-up period may be needed before stating the absolute equivalence of the two regimens used.

AB - During the last few years, morphological, immunohistochemical, and genetic findings have placed anaplastic large cell lymphoma (ALCL) as a distinct clinicopathologic entity, and several reports have focused on the existence of different subtypes of the tumor. Particular attention has been paid to the ALCL-Hodgkin's-like (HL) subtype, which seems to be on the border between Hodgkin's disease (HD) and high-grade non-Hodgkin's lymphoma (HG- NHL). From September 1994 to July 1997, during the course of an Italian multicentric trial, 40 ALCL-HLs were randomized to receive as front-line chemotherapy MACOP-B (methotrexate with leucovorin, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin - a third- generation HG-NHL regimen) or ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine - a scheme specific for HD). All patients with bulky disease in the mediastinum at diagnosis underwent local radiotherapy after the chemotherapeutic program. Complete response (CR) was achieved in 17 of the 19 (90%) patients who were treated with MACOP-B, and in 19 of the 21 (91%) patients who were administered ABVD. The probability of relapse-free survival, projected at 32 months, was 94% for the MACOP-B subset and 91% for the ABVD subset. The majority of patients with mediastinal bulky disease obtained CR (evaluated with 67Ga single photon emission computed tomography [SPECT]) after their radiotherapy. The present study suggests that ALCL-HL, in line with its borderline status, responds in an equivalent way to third- generation chemotherapy for HG-NHL and to conventional HD treatment in terms of both CR and relapse-free survival rates. However, as to the latter, a longer follow-up period may be needed before stating the absolute equivalence of the two regimens used.

UR - http://www.scopus.com/inward/record.url?scp=0032147217&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032147217&partnerID=8YFLogxK

M3 - Article

C2 - 9680346

AN - SCOPUS:0032147217

VL - 92

SP - 790

EP - 794

JO - Blood

JF - Blood

SN - 0006-4971

IS - 3

ER -